Press release
United States Neurodegenerative Disease Therapeutics Market to Reach $28.78B by 2033 - Driven by Aging Populations & Innovative Therapies | Biogen, Roche, Eli Lilly, Novartis, Takeda, Eisai, AbbVie, Pfizer, Merck, Otsuka
Neurodegenerative Disease Therapeutics Market
Neurodegenerative disease therapeutics focus on treating progressive disorders that affect the nervous system, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The market is expanding due to the rising prevalence of aging populations, increasing awareness of neurodegenerative conditions, and ongoing advancements in drug development and targeted therapies. Key therapeutic approaches include small molecule drugs, monoclonal antibodies, gene therapies, and neuroprotective agents designed to slow disease progression, alleviate symptoms, and improve patient quality of life.
📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Neurodegenerative Disease Therapeutics Market Landscape:- https://datamintelligence.com/download-sample/neurodegenerative-disease-therapeutics-market?rk
☛ Neurodegenerative Disease Therapeutics Market Recent Developments 2025:
United States: Recent Industry Developments
✅ In August 2025, Biogen launched its next-generation Alzheimer's therapeutics targeting amyloid and tau proteins, aiming to slow disease progression in early-stage patients.
✅ In July 2025, Roche expanded its Parkinson's disease therapy portfolio with innovative monoclonal antibodies and small molecules in clinical trials across the U.S.
✅ In June 2025, Eli Lilly partnered with U.S. research institutions to advance novel neuroprotective agents for ALS and multiple sclerosis, emphasizing disease-modifying approaches.
Europe: Recent Industry Developments
✅ In July 2025, Novartis deployed gene therapy and small-molecule therapeutics for neurodegenerative diseases across EU clinical programs.
✅ In June 2025, UCB Pharma launched next-generation therapies for Alzheimer's and Parkinson's disease in European markets, focusing on symptomatic and disease-modifying effects.
✅ In May 2025, Axsome Therapeutics partnered with European research centers to accelerate clinical trials for novel CNS therapeutics, including depression and neurodegenerative indications.
Japan: Recent Industry Developments
✅ In July 2025, Takeda Pharmaceutical launched innovative neurodegenerative disease therapeutics for Alzheimer's and Parkinson's in Japan, incorporating precision medicine strategies.
✅ In June 2025, Daiichi Sankyo expanded its CNS-focused therapeutic portfolio, targeting ALS and other neurodegenerative disorders.
✅ In May 2025, Eisai Co., Ltd. partnered with hospitals to implement next-generation treatments for dementia and Alzheimer's disease, enhancing patient care and clinical outcomes.
☛ Neurodegenerative Disease Therapeutics Market Trends:
Technological Advancements: Innovations in gene therapy, biologics, monoclonal antibodies, and disease-modifying drugs are creating new treatment opportunities. AI and bioinformatics are also accelerating drug discovery, target validation, and clinical trial optimization.
Rising Disease Burden: Increasing aging populations worldwide and higher incidence of Alzheimer's and Parkinson's disease are major drivers for therapeutic development and market expansion.
Pipeline Expansion: A growing number of clinical trials focusing on disease-modifying therapies is fueling investment and boosting market growth prospects.
Regional Insights: North America dominates due to strong research infrastructure, regulatory support, and high healthcare spending. Asia-Pacific is emerging rapidly, supported by aging populations, government healthcare initiatives, and growing biotech R&D.
Challenges: High R&D costs, long development timelines, regulatory hurdles, and the complexity of neurodegenerative disease mechanisms remain significant barriers.
Strategic Initiatives: Companies are focusing on strategic collaborations, licensing agreements, and advanced therapy development to expand their neurodegenerative disease portfolios and accelerate commercialization.
☛ Neurodegenerative Disease Therapeutics Market Competitve Landscape:
AbbVie Inc., Amneal Pharmaceuticals LLC., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd., Orion Corporation.
Research Methodology
We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.
📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/neurodegenerative-disease-therapeutics-market
☛ Segment Covered in the Neurodegenerative Disease Therapeutics Market:
By Drug Class: Dopamine Agonists | Decarboxylase Inhibitors | Cholinesterase Inhibitors | Immunomodulators | Others
By Disease Type: Parkinson's Disease | Amyotrophic Lateral Sclerosis | Alzheimer's Disease | Huntington Disease | Others
By Route of Administration: Oral | Injection | Transdermal
☛ This Report Includes:
✔ Comprehensive go-to-market strategies with actionable insights.
✔ Unbiased evaluation of overall market performance.
✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.
✔ Tailored regional and country-level reports with detailed localized analysis available on request.
✔ Identification of niche segments and high-growth regions presenting strong opportunities.
✔ Accurate regional forecasts using both top-down and bottom-up approaches.
📌 Get Corporate Access to Live Neurodegenerative Disease Therapeutics Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=neurodegenerative-disease-therapeutics-market
☛ Regional Analysis for Neurodegenerative Disease Therapeutics Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
☛ Frequently asked questions:
➠ What is the global sales, production, consumption, import, and export value of the Neurodegenerative Disease Therapeutics Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Neurodegenerative Disease Therapeutics Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Neurodegenerative Disease Therapeutics Market?
➠ What sales, marketing, and distribution channels are used globally?
📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription
☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Neurodegenerative Disease Therapeutics Market to Reach $28.78B by 2033 - Driven by Aging Populations & Innovative Therapies | Biogen, Roche, Eli Lilly, Novartis, Takeda, Eisai, AbbVie, Pfizer, Merck, Otsuka here
News-ID: 4203454 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Biomass Briquette Market to Grow at 7% CAGR from 2025 to 2031, Led by North Amer …
The Biomass Briquette Market is expected to expand at a CAGR of about 7% from 2025 to 2031 as industries and households increasingly adopt sustainable and eco‐friendly solid fuel alternatives to traditional fossil fuels, driven by rising energy demand and environmental concerns.
Growth is supported by increasing demand across key applications such as industrial fuel, power generation, cooking fuel, and residential heating, driven by abundant agricultural and forestry residues that are…
Protein Engineering Market to Grow at 15.6% CAGR from 2025 to 2033, Driven by No …
The global protein engineering market reached US$ 2,854.54 Million in 2024 and is expected to reach US$ 8,646.10 Million by 2033, growing at a CAGR of 15.6 % from 2025 ro 2033 as demand for tailored biological solutions accelerates across pharmaceuticals, biotechnology, diagnostics, and industrial applications.
Growth is supported by increasing adoption of advanced protein modification, design and synthesis techniques to develop high‐efficacy therapeutics, enzymes, and biomaterials, driven by rising…
Substation Automation Market to Reach USD 67B by 2031 at 6.5% CAGR | Driven by R …
According to DataM Intelligence, the Substation Automation Market reached USD 41 billion in 2022 and is expected to reach USD 67 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2024-2031).The global Substation Automation Market is undergoing a significant transformation as utilities and grid operators modernize aging infrastructure and transition toward digital substations. Substation automation systems (SAS) integrate intelligent electronic devices (IEDs), communication networks, SCADA platforms,…
Aluminum Market to Reach US$ 401.60 Billion by 2032 Driven by Infrastructure Gro …
The Aluminum Market reached US$ 231.82 billion in 2024 and is expected to reach US$ 401.60 billion by 2032, growing at a CAGR of 7.11% during the forecast period 2025-2032.
Growth is driven by rising demand across construction, automotive, aerospace, packaging, and electrical industries, where aluminum is valued for its lightweight properties, corrosion resistance, high strength-to-weight ratio, and recyclability. Increasing focus on vehicle lightweighting, electric vehicle production, and sustainable packaging solutions…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
